When injected peripherally, TrkB-ago could break through the blood-brain barrier (BBB) and activate downstream signaling in hypothalamus [40], so that peripheral injection of TrkB-ago may be a more powerful way to treat obesity of Bdnf-e2−/− mice. Here, NTRK2 is linked to obesity due to melanocortin 4 receptor deficiency.